12月31日,艾伯维宣布与苏州泽璟生物制药达成合作和授权许可协议,总价值最高12亿美元,包括1亿美元预付款、最高6000万美元近期临床和选择权付款,以及若行使选择权后最高10.75亿美元开发、注册和销售里程碑付款,外加中国以外销售的分级特许权使用费(高个位数至中双位数百分比)。艾伯维获得ZG006(alveltamig)中国以外全球独家开发和商业化权益;泽璟制药保留中国的全部权益。ZG006为靶向...
Source Link12月31日,艾伯维宣布与苏州泽璟生物制药达成合作和授权许可协议,总价值最高12亿美元,包括1亿美元预付款、最高6000万美元近期临床和选择权付款,以及若行使选择权后最高10.75亿美元开发、注册和销售里程碑付款,外加中国以外销售的分级特许权使用费(高个位数至中双位数百分比)。艾伯维获得ZG006(alveltamig)中国以外全球独家开发和商业化权益;泽璟制药保留中国的全部权益。ZG006为靶向...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.